Author: Ken Dropiewski

BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

Proposal No. 1 (The Acquisition Proposal) to be adjourned pending final NASDAQ approval; Company operations, financings and closing of the merger transaction remain not impactedLOS ANGELES and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today provided an update regarding the status of the merger and related proxy materials. The merger transaction closed on May 28, 2025, under the previously executed Share Purchase Agreement. As part of this transaction, 19.99% of BioSig shares are already issuable to Streamex shareholders, with the remaining issuances pending Nasdaq approval. In connection with the Company’s Schedule 14A filings, the Board of Directors has determined that, due to pending Nasdaq approval, Proposal No. 1 (the Acquisition Proposal) will not be acted upon at the September 5, 2025, Special Meeting and will instead be adjourned to a later date to be announced by the Company at the Special Meeting. While the merger with Streamex has already been consummated, the issuance of the remaining shares requires formal stockholder approval, which will be obtained at the reconvened Special Meeting. Importantly, the removal of Proposal No. 1 from the proxy does not impact: The closing of the merger;The timing of closings of the Company’s financings; orThe operations of the Company. All other proposals outlined in the Company’s definitive proxy statement will proceed as planned at the September 5, 2025 Special Meeting. About Streamex Streamex is an RWA tokenization company building Institutional grade infrastructure to bring the gold and commodities market on chain, enabled by a gold denominated treasury and tokenization technology powering the modern commodities market. Streamex is a wholly owned subsidiary of BioSig Technologies, Inc. About BioSig Technologies BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP™ Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the acquisition will be obtained, and whether we will be able to maintain compliance with Nasdaq’s listing criteria in connection with the acquisition and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled “Risk Factors” in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law. Contacts BioSig/Streamex Press & Investor Relations: Adele CareyAlliance Advisors Investor Relationsacarey@allianceadvisors.comHenry McPhieCEO of BioSig, Co-Founder of Streamexcontact@Streamex.comhttps://www.streamex.com/https://x.com/streamex

Compelling data at ESC Congress 2025 reinforce safety and performance of the Medtronic OmniaSecure™ defibrillation lead, including in the left bundle branch area

The upcoming U.S. launch of the small-diameter OmniaSecure defibrillation lead will introduce the first FDA-approved lead for both adults and adolescent pediatric patients Cardiac Rhythm Management At the 2025 European Society of Cardiology (ESC) Congress in Madrid, researchers presented three new datasets reinforcing the safety and performance of the OmniaSecure™ […]

Medtronic receives approval for Symplicity Spyral™ Renal Denervation System in Japan

Japan is now the 77th country to receive regulatory approval for the Symplicity Spyral Renal Denervation System Medtronic, a global leader in healthcare technology, today announced it received approval in Japan from the Pharmaceuticals and Medical Devices Agency (PMDA) for its Symplicity Spyral™ renal denervation (RDN) system, also known as […]

SCD-PROTECT publication: High SCD risk despite modern GDMT across 19,500+ LifeVest® patients

September 2, 2025 – CHELMSFORD, MASS. – ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, is highlighting the recent European Heart Journal publication of SCD-PROTECT, an independent clinical trial designed to specifically evaluate the risk of sudden cardiac death (SCD) in the early post-MI/CAD and […]

Medtronic Evolut TAVR systems receive FDA approval for expanded Redo TAVR indication

Medtronic plc, a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for the expanded Redo-TAVR indication of the Evolut™ transcatheter aortic valve replacement (TAVR) system. This approval allows for the implantation of a new Evolut transcatheter aortic valve (TAV) inside any failed […]

Imperative Care Announces FDA Clearance of Symphony Thrombectomy System, the First Large-Bore Continuous Vacuum System for Treatment of Pulmonary Embolism

CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Symphony® Thrombectomy System to treat pulmonary embolism (PE), a life-threatening condition caused by blood clots blocking an artery in the lungs. This clearance expands the use of Symphony – previously for the treatment of […]

Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting

The Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders The stockholder approved proposals provide the foundation for Windtree revenue generating deals in environmental services Windtree is choosing to focus on environmental services and other revenue generating businesses – the Company will not move forward with the cryptocurrency treasury strategy Company continues to move forward with potential deals for both biotech assets that will bring in near term cash and long term milestones and royalties WARRINGTON, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that key proposals for its corporate strategy were approved at the Special Stockholder Meeting on August 28, 2025. The proxy voting reached a quorum prior to the meeting date and all ten of the proposals were approved by stockholder proxy voters. Two proposals were related to the environmental services company transaction planned by the Company. That transaction will provide a path to revenue generation and the opportunity to add additional environmental services companies for scale. The corporate plan targets potential profitability for the Windtree Environmental Services division when a future acquisition is completed. Another key area for the Company approved by stockholders is planning for growth through potential deals by increasing authorized shares from 125 million to 1 billion. Flexibility of financial instruments that could utilize equity is provided by this stockholder approved proposal. To ensure we are focused on our core strategy and as previously stated by the Company, it plans to find partnership for the cardiovascular and oncology biotech assets for continued development. In 2024, Windtree had $8.8 million of expense for research and development (R&D) related to the cardiovascular program. The Company believes that a partnership could eliminate further R&D expenses. The Company believes that focusing on its new core business will be beneficial for its stockholders. The Company has chosen not to move forward with the cryptocurrency treasury strategy. “We thank our stockholders for supporting our strategic plan in their proxy voting,” said Jed Latkin, Chief Executive Officer of Windtree. “Our forward-looking plan to generate revenue and future profit with our assets is underway and we are making progress every day. We believe that focusing on our new core business will be beneficial to our stockholders. As such, we have chosen not to move forward with the cryptocurrency treasury strategy and we hope to successfully partner our biotech assets in the near term, which will eliminate R&D expenses which were nearly $9 million in 2024. We look forward to providing updates on this Company transformation.” About Windtree Therapeutics, Inc.Windtree Therapeutics, Inc. is a diversified company with several divisions and focused on becoming a revenue generating company with future profitability. Forward Looking StatementsThe Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: risks related to the Company’s ability to begin its environmental services business, wind down the crypto currency strategy, and manage costs and execute on its operational and budget plans. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release. Contact Information:Eric Curtisecurtis@windtreetx.com

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of ageTHE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of clinical data was presented Sunday, August 31, during an oral presentation at the European Society of Cardiology (ESC) 2025 Congress in Madrid, Spain. It is well-established that the incidence of stroke and myocardial infarction (MI, or heart attack), known collectively as major cardiovascular adverse events (MACE), rises with age, as does incidence of heart failure (HF) events. Sotagliflozin, a dual sodium-glucose cotransport 1 and 2 (SGLT-1 and SGLT-2) inhibitor, was approved by the FDA based on its demonstrated efficacy in improving HF endpoints in patients with chronic kidney disease (CKD) or HF. This latest Lexicon-funded analysis examined how the efficacy of sotagliflozin varies with age, particularly among older adults, and used data pooled from the two previous pivotal Phase 3 studies of sotagliflozin, SCORED and SOLOIST-WHF. The robust data set included nearly 12,000 participants, about 70% of whom were 65 or older. This age group represents a very large population in which type 2 diabetes, CKD and/or worsening HF are relatively common. Patients were evaluated by age, both categorically (≥65 years vs